[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]  aponia_analytics [@AponiaAnalytics](/creator/twitter/AponiaAnalytics) on x 4961 followers Created: 2025-07-20 21:27:43 UTC 🦉 REWIND showed dulaglutide reduced MACE in lower-risk T2DM patients; benefits driven by nonfatal stroke. But XX% discontinued by study end. Tolerability remains a limiting factor in long-term outcomes. #GLP1 #stroke $NVO $LLY $ZLDPF $VANI $HIMS $AZN XXX engagements  **Related Topics** [manat](/topic/manat) [hims](/topic/hims) [$hims](/topic/$hims) [$vani](/topic/$vani) [$zldpf](/topic/$zldpf) [$lly](/topic/$lly) [$nvo](/topic/$nvo) [stocks healthcare](/topic/stocks-healthcare) [Post Link](https://x.com/AponiaAnalytics/status/1947045781233344553)
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
aponia_analytics @AponiaAnalytics on x 4961 followers
Created: 2025-07-20 21:27:43 UTC
🦉 REWIND showed dulaglutide reduced MACE in lower-risk T2DM patients; benefits driven by nonfatal stroke. But XX% discontinued by study end. Tolerability remains a limiting factor in long-term outcomes.
#GLP1 #stroke $NVO $LLY $ZLDPF $VANI $HIMS $AZN
XXX engagements
Related Topics manat hims $hims $vani $zldpf $lly $nvo stocks healthcare
/post/tweet::1947045781233344553